View : 333 Download: 0
Comparative effectiveness of treatment options after conventional DMARDs failure in rheumatoid arthritis
- Comparative effectiveness of treatment options after conventional DMARDs failure in rheumatoid arthritis
- Sung Y.-K.; Cho S.-K.; Kim D.; Choi C.-B.; Won S.; Bang S.-Y.; Cha H.-S.; Choe J.-Y.; Chung W.T.; Hong S.-J.; Jun J.-B.; Kim H.A.; Kim J.; Kim S.-K.; Kim T.-H.; Lee H.-S.; Lee J.; Lee S.-S.; Lee S.W.; Lee Y.-A.; Nah S.-S.; Suh C.-H.; Yoo D.-H.; Yoon B.Y.; Bae S.C.; For the BIOPSY and KORONA investigators
- Ewha Authors
- SCOPUS Author ID
- Issue Date
- Journal Title
- Rheumatology International
- Rheumatology International vol. 37, no. 6, pp. 975 - 982
- Anti-TNF drugs; DMARDs; HAQ; Quality of life; Rheumatoid arthritis
- Springer Verlag
- SCIE; SCOPUS
- Document Type
- Objective: To compare the clinical effectiveness of two treatment strategies for active rheumatoid arthritis (RA) refractory to conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs): starting TNF inhibitors (TNFIs) or changing csDMARDs. Methods: We used two nationwide Korean RA registries for patient selection. TNFI users were selected from the BIOPSY, which is an inception cohort of RA patients starting biologic DMARDs. As a control group, we selected RA patients with moderate or high disease activity from the KORONA database whose treatment was changed to other csDMARDs. After comparing baseline characteristics between the two groups in either unmatched or propensity score matched cohorts, we compared potential differences in the 1-year remission rate as a primary outcome and changes in HAQ-DI and EQ-5D scores as secondary outcomes. Results: A total of 356 TNFI starters and 586 csDMARD changers were identified from each registry as unmatched cohorts, and 294 patients were included in the propensity score matched cohort. In the intention-to-treat analysis, TNFI starters had higher 1-year remission rates than csDMARD changers in both unmatched (19.1 vs. 18.4%, p < 0.01) and matched cohorts (19.7 vs. 15.0%, p < 0.01). In per protocol analysis, TNFI starters had much higher remission rates in unmatched (37.2 vs. 28.0%, p = 0.04) and matched cohorts (35.4 vs. 19.1%, p = 0.04). However, in matched cohorts, no significant differences were observed between two groups in HAQ-DI and EQ-5D scores. Conclusions: We compared the clinical effectiveness of the two treatment strategies for active RA refractory to csDMARDs. TNFI starters showed higher 1-year remission rates than csDMARD changers. © 2017, Springer-Verlag Berlin Heidelberg.
- Appears in Collections:
- 의과대학 > 의학과 > Journal papers
- Files in This Item:
There are no files associated with this item.
- RIS (EndNote)
- XLS (Excel)
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.